Nomura Securities lifts price target from $68 to $83! They said that positive phase 2 data in pancreatic cancer was just the beginning they are now incorporating US sales of Jakafi in breast and non-small lung cancer into their model! I would not sell a single share because they are now laughing everytime a single sale order comes across the tape! They know this is heading much higher. This may be a top 3 biotech of 2014 but hey we already knew that!